453 related articles for article (PubMed ID: 17851052)
1. Exposure to quinolones is associated with carbapenem resistance among colistin-susceptible Acinetobacter baumannii blood isolates.
Kopterides P; Koletsi PK; Michalopoulos A; Falagas ME
Int J Antimicrob Agents; 2007 Nov; 30(5):409-14. PubMed ID: 17851052
[TBL] [Abstract][Full Text] [Related]
2. The significance of Acinetobacter baumannii bacteraemia compared with Klebsiella pneumoniae bacteraemia: risk factors and outcomes.
Robenshtok E; Paul M; Leibovici L; Fraser A; Pitlik S; Ostfeld I; Samra Z; Perez S; Lev B; Weinberger M
J Hosp Infect; 2006 Nov; 64(3):282-7. PubMed ID: 16930770
[TBL] [Abstract][Full Text] [Related]
3. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections.
Saballs M; Pujol M; Tubau F; Peña C; Montero A; Domínguez MA; Gudiol F; Ariza J
J Antimicrob Chemother; 2006 Sep; 58(3):697-700. PubMed ID: 16895941
[TBL] [Abstract][Full Text] [Related]
4. Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy.
Falagas ME; Kasiakou SK; Rafailidis PI; Zouglakis G; Morfou P
J Antimicrob Chemother; 2006 Jun; 57(6):1251-4. PubMed ID: 16627593
[TBL] [Abstract][Full Text] [Related]
5. Risk factors and clinical outcomes of multidrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Thailand.
Anunnatsiri S; Tonsawan P
Southeast Asian J Trop Med Public Health; 2011 May; 42(3):693-703. PubMed ID: 21706949
[TBL] [Abstract][Full Text] [Related]
6. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study.
Matthaiou DK; Michalopoulos A; Rafailidis PI; Karageorgopoulos DE; Papaioannou V; Ntani G; Samonis G; Falagas ME
Crit Care Med; 2008 Mar; 36(3):807-11. PubMed ID: 18431267
[TBL] [Abstract][Full Text] [Related]
7. A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia.
Nutman A; Glick R; Temkin E; Hoshen M; Edgar R; Braun T; Carmeli Y
Clin Microbiol Infect; 2014 Dec; 20(12):O1028-34. PubMed ID: 24930471
[TBL] [Abstract][Full Text] [Related]
8. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia.
Huang ST; Chiang MC; Kuo SC; Lee YT; Chiang TH; Yang SP; Ti-Yin ; Chen TL; Fung CP
J Microbiol Immunol Infect; 2012 Oct; 45(5):356-62. PubMed ID: 22575430
[TBL] [Abstract][Full Text] [Related]
9. Mortality risk factors of Acinetobacter baumannii bacteraemia.
Choi JY; Park YS; Kim CO; Park YS; Yoon HJ; Shin SY; Kim YA; Song YG; Yong D; Lee K; Kim JM
Intern Med J; 2005 Oct; 35(10):599-603. PubMed ID: 16207259
[TBL] [Abstract][Full Text] [Related]
10. Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia.
Metan G; Sariguzel F; Sumerkan B
Eur J Intern Med; 2009 Sep; 20(5):540-4. PubMed ID: 19712862
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.
Song JY; Kee SY; Hwang IS; Seo YB; Jeong HW; Kim WJ; Cheong HJ
J Antimicrob Chemother; 2007 Aug; 60(2):317-22. PubMed ID: 17540672
[TBL] [Abstract][Full Text] [Related]
12. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model.
Montero A; Ariza J; Corbella X; Doménech A; Cabellos C; Ayats J; Tubau F; Borraz C; Gudiol F
J Antimicrob Chemother; 2004 Dec; 54(6):1085-91. PubMed ID: 15546972
[TBL] [Abstract][Full Text] [Related]
13. Emergence of carbapenem resistance in Acinetobacter baumannii in the Czech Republic is associated with the spread of multidrug-resistant strains of European clone II.
Nemec A; Krízová L; Maixnerová M; Diancourt L; van der Reijden TJ; Brisse S; van den Broek P; Dijkshoorn L
J Antimicrob Chemother; 2008 Sep; 62(3):484-9. PubMed ID: 18477708
[TBL] [Abstract][Full Text] [Related]
14. Emergence and spread of carbapenem-resistant strains of Acinetobacter baumannii in a tertiary-care hospital in Poland.
Wroblewska MM; Towner KJ; Marchel H; Luczak M
Clin Microbiol Infect; 2007 May; 13(5):490-6. PubMed ID: 17331123
[TBL] [Abstract][Full Text] [Related]
15. Identification of multidrug- and carbapenem-resistant Acinetobacter baumannii in Canada: results from CANWARD 2007.
McCracken M; DeCorby M; Fuller J; Loo V; Hoban DJ; Zhanel GG; Mulvey MR
J Antimicrob Chemother; 2009 Sep; 64(3):552-5. PubMed ID: 19578083
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for carbapenem-resistant Acinetobacter baumannii infections at a tertiary care hospital in New Caledonia, South Pacific.
Le Hello S; Falcot V; Lacassin F; Mikulski M; Baumann F
Scand J Infect Dis; 2010 Dec; 42(11-12):821-6. PubMed ID: 20560868
[TBL] [Abstract][Full Text] [Related]
17. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii.
Motaouakkil S; Charra B; Hachimi A; Nejmi H; Benslama A; Elmdaghri N; Belabbes H; Benbachir M
J Infect; 2006 Oct; 53(4):274-8. PubMed ID: 16442632
[TBL] [Abstract][Full Text] [Related]
18. Risk factors and impact of nosocomial Acinetobacter baumannii bloodstream infections in the adult intensive care unit: a case-control study.
Jang TN; Lee SH; Huang CH; Lee CL; Chen WY
J Hosp Infect; 2009 Oct; 73(2):143-50. PubMed ID: 19716203
[TBL] [Abstract][Full Text] [Related]
19. Nosocomial multidrug-resistant Acinetobacter baumannii in the neonatal intensive care unit in Gaza City, Palestine.
Al Jarousha AM; El Jadba AH; Al Afifi AS; El Qouqa IA
Int J Infect Dis; 2009 Sep; 13(5):623-8. PubMed ID: 19144555
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for 30-day mortality in patients with carbapenem-resistant Acinetobacter baumannii during an outbreak in an intensive care unit.
Prates CG; Martins AF; Superti SV; Lopes FS; Ramos F; Cantarelli VV; Zavascki AP
Epidemiol Infect; 2011 Mar; 139(3):411-8. PubMed ID: 20513254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
